






NANOLOGICA



NANOLOGICA


NANOPOROUS SILICA PARTICLES FOR PULMONARY DELIVERY

Nanologica develops nanoporous silica particles tailored for pulmonary drug delivery. Nanologica's proprietary NLAB Silica™ particles solves problems in pharmaceutical formulations by improving solubility, enhancing bioavailability and protecting APIs from degradation.




Nanologica produces spherical particles in the size range of 2 μm to 5 μm with narrow particle size distribution to reach the desired target site in the lung. The particles are non-aggregating, carry a high drug load, and offer a controlled and sustained release profile.

The particles are soluble in simulated lung fluid.



NLAB Silica™



- Nanoporous amorphous silica
- GRAS approved excipient
- Tuneable particle and pore size
- High loading up to 50%
- Free-flowing powder

Business model

- Licensing agreements/ technology transfer
- Feasibility studies
- Fee for service contracts
- Development of own assets



Contact

Professor Adam Feiler | Chief Technical Officer
adam.feiler@nanologica.com

Ms. Kia Bengtsson | Director Clinical Development
kia.bengtsson@nanologica.com